002038.SZ

Beijing SL Pharmaceutical Co., Ltd. [002038.SZ] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

002038.SZ Stock Summary

In the News

002038.SZ Financial details

Company Rating
-
Market Cap
8.67B
Income
311.05M
Revenue
999.82M
Book val./share
-
Cash/share
-
Dividend
0.1
Dividend %
1.06%
Employees
757
Optionable
No
Shortable
Yes
Earnings
24 Apr 2024
P/E
31.55
Forward P/E
-
PEG
-12.21
P/S
9.76
P/B
1.73
P/C
-
P/FCF
-1312.44
Quick Ratio
4.58
Current Ratio
7.85
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
0.3
EPS next Y
-
EPS next Q
-
EPS this Y
-43.9%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-22.64%
Revenue last 5Y
-13.49%
Revenue Q/Q
-32.69%
EPS Q/Q
-99.64%
-
-
-
-
SMA20
-25%
SMA50
-25%
SMA100
-14.29%
Inst Own
-
Inst Trans
-
ROA
5%
ROE
6%
ROC
0.06%
Gross Margin
82%
Oper. Margin
36%
Profit Margin
31%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
7.05-16.09
52W High
-60.88%
52W Low
-10.57%
RSI
30
Rel Volume
0.83
Avg Volume
22.07M
Volume
18.36M
Perf Week
-3.99%
Perf Month
-18.81%
Perf Quarter
-
Perf Half Y
-19.33%
-
-
-
-
Beta
0.346
-
-
Volatility
0.15%, 0.65%
Prev Close
2.12%
Price
6.26
Change
1.95%

002038.SZ Financial Performance

002038.SZ Dividend History

002038.SZ Frequently Asked Questions

What is Beijing SL Pharmaceutical Co., Ltd. stock symbol ?

Beijing SL Pharmaceutical Co., Ltd. is a CN stock and trading under the symbol 002038.SZ

What is Beijing SL Pharmaceutical Co., Ltd. stock quote today ?

Beijing SL Pharmaceutical Co., Ltd. stock price is $6.26 today.

Is Beijing SL Pharmaceutical Co., Ltd. stock public?

Yes, Beijing SL Pharmaceutical Co., Ltd. is a publicly traded company.

Something similar

Top by Market Cap
BRK-B
JPM
1YD.DE
BRK-A
AAPL
Same Sector
ARGX
CYCCP
ZSAN
GABA.ST
EGTX.ST
Same Price Range
HMCA.L
002591.SZ
ATC.WA
ATH.TO
HOPE
Similar Market Cap
KANORICHEM.NS
600338.SS
1446.T
JVASX
CORE-D.ST

Company Profile

Healthcare Drug Manufacturers - Specialty & Generic
  • Volume Average 22.07M
  • Market Capitalization 8.67B
  • Employee 757
  • CEO Dr. Mingbo Xu
  • Headquarters Beijing,CN
  • IPO Date 2004-09-09
  • Website https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, researches, develops, produces, and markets genetic engineering and related drugs in the People's Republic of China and internationally. The company's finished formulations includes temozolomide; arsenic trioxide; lenalidomide; docetaxel; paclitaxel; filgrastim Recombinant human granulocyte colony-stimulating factor; recombinant human interleukin-11; recombinant human interleukin-2; thymopentin; vinorelbine bitartrate; hydroxyl-camptothecine; nimustine hydrochloride; asparaginase; PEG L-asparaginase; calcium foliate; recombinant human basic fibroblast growth factor; ciclosporin; mycophenolate mofetil dispersible; ornidazole; adefovir dipivoxil; levofloxacin hydrochloride; azithromycin; ribavirin; tenofovir disoproxil fumarate; valacylovir hydrochloride; lysozyme; stavudine; tropisetron hydrochloride; granisetron hydrochloride; omeprazole; ademetionine 1,4-butanedisulfonate; glutathione; enoxaparin sodium; coenzyme complex; ginkgo biloba extract; simvastatin; telmisartan; naftopidil; nicergoline; zaleplon; cytidine disodium triphosphate; febuxostat; risedronate sodium; loratadine dispersible; somatostatin; octreotide acetate; calcitonin (salmon); paracetamol and tramadol hydrochloride; and etodolac. It also offers active pharmaceutical ingredients. The company was formerly known as Beijing BaiLuyuan Bio-Pharmaceutical Co., Ltd and changed its name to Beijing SL Pharmaceutical Co., Ltd. in 1998. Beijing SL Pharmaceutical Co., Ltd. was founded in 1994 and is based in Beijing, the People's Republic of China.